Literature DB >> 19804416

LRRK2 in Parkinson's disease: biochemical functions.

Vasanti S Anand1, Steven P Braithwaite.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a large, complex, multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein interaction domains. Mutations linked to autosomal dominant forms of Parkinson's disease result in amino acid changes throughout the protein and alterations in both its enzymatic properties and interactions. The best characterized mutation to date, G2019S, leads to increased kinase activity, and mutations in the GTPase domain, such as R1441C and R1441G, have also been reported to influence kinase activity. Therefore, an examination of LRRK2's properties as a kinase is important for understanding the mechanisms underlying the disorder and has the potential to lead to therapeutics. These findings also suggest that there may be complex interplay between the functional domains of LRRK2. Here, we review LRRK2's biochemical functions based on structural and kinetic studies of the enzymatic domains, its potential substrates and the role of its interactions. Despite the field's embryonic understanding of the true relevance of these substrates and interactions, initial studies are providing clues with respect to its pathophysiological functions. Together, these findings should increase our understanding of mechanisms underlying Parkinson's disease and place LRRK2 as a unique molecular target for effective therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804416     DOI: 10.1111/j.1742-4658.2009.07341.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  29 in total

1.  The ROCO kinase QkgA is necessary for proliferation inhibition by autocrine signals in Dictyostelium discoideum.

Authors:  Jonathan E Phillips; Richard H Gomer
Journal:  Eukaryot Cell       Date:  2010-08-13

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.

Authors:  Andrea Meixner; Karsten Boldt; Marleen Van Troys; Manor Askenazi; Christian J Gloeckner; Matthias Bauer; Jarrod A Marto; Christophe Ampe; Norbert Kinkl; Marius Ueffing
Journal:  Mol Cell Proteomics       Date:  2010-09-27       Impact factor: 5.911

4.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

Authors:  Nigel Ramsden; Jessica Perrin; Zhao Ren; Byoung Dae Lee; Nico Zinn; Valina L Dawson; Danny Tam; Michael Bova; Manja Lang; Gerard Drewes; Marcus Bantscheff; Frederique Bard; Ted M Dawson; Carsten Hopf
Journal:  ACS Chem Biol       Date:  2011-08-10       Impact factor: 5.100

5.  Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.

Authors:  Yuan Liu; Travis B Lear; Manish Verma; Kent Zq Wang; P Anthony Otero; Alison C McKelvey; Sarah R Dunn; Erin Steer; Nicholas W Bateman; Christine Wu; Yu Jiang; Nathaniel M Weathington; Mauricio Rojas; Charleen T Chu; Bill B Chen; Rama K Mallampalli
Journal:  JCI Insight       Date:  2020-06-04

6.  High-Resolution Melting Analysis as a Developed Method for Genotyping the PD Susceptibility Loci in LRRK2 Gene.

Authors:  Enzhu Jiang; Fengrui Li; Chenchen Jing; Pei Li; Honggang Cui; Baojie Wang; Mei Ding; Hao Pang
Journal:  J Clin Lab Anal       Date:  2014-05-21       Impact factor: 2.352

7.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

Review 8.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

9.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Authors:  R Jeremy Nichols; Nicolas Dzamko; Nicholas A Morrice; David G Campbell; Maria Deak; Alban Ordureau; Thomas Macartney; Youren Tong; Jie Shen; Alan R Prescott; Dario R Alessi
Journal:  Biochem J       Date:  2010-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.